Your browser doesn't support javascript.
loading
Effect of Danqi Shuxin capsule in treating patients with coronary heart disease complicated with hypercholesterolemia / 中国生化药物杂志
Chinese Journal of Biochemical Pharmaceutics ; (6): 125-127, 2017.
Article Dans Chinois | WPRIM | ID: wpr-509635
ABSTRACT
Objective To observe the effect of Danqi Shuxin Capsule on patients with coronary heart disease complicated with hypercholesterolemia.Methods 140 cases of patients patients with coronary heart disease complicated with hypercholesterolemia from February 2016 to October 2016 in our hospital were selected, according to different treatment divided into observation group and control group,the control group treated with Rosuvastatin Calcium,the observation group treated with Danqi Shuxin capsule on the basis of the control group , observation and compared the change of hs-CRP, Hcy, TNF-α, blood lipid, blood sugar levels between two groups.Results After treatment,the levels of hs-CRP,Hcy and TNF-αin the two groups were significantly decreased (P<0.05),and the levels of hs-CRP, Hcy and TNF-αin the observation group were significantly lower than those in the control group (P<0.05).Compared with before treatment, the levels of TC, TG and LDL-C in the two groups were significantly decreased, HDL-C levels were significantly increased,the difference was statistically significant (P<0.05); the levels of TC, TG and LDL-C in the observation group were significantly lower than those in the control group (P<0.05).There was no significant change in FPG levels before and after treatment. Conclusion Danqi Shuxin capsule can effectively reduce the hs-CRP and Hcy levels in CHD patients with hypercholesterolemia , improve blood lipid levels, while reduce the level of inflammatory factors.

Texte intégral: Disponible Indice: WPRIM (Pacifique occidental) langue: Chinois Texte intégral: Chinese Journal of Biochemical Pharmaceutics Année: 2017 Type: Article

Documents relatifs à ce sujet

MEDLINE

...
LILACS

LIS

Texte intégral: Disponible Indice: WPRIM (Pacifique occidental) langue: Chinois Texte intégral: Chinese Journal of Biochemical Pharmaceutics Année: 2017 Type: Article